Health regulators from Germany and France ordered the drug to be taken off the market in 2011, after an analysis... revealed that some users faced an increased risk of developing bladder cancer or heart problems.
New York, NY (PRWEB) April 29, 2013
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, is responding to the results of the first Actos trial, which took place in Los Angeles and has concluded. In an April 26, 2013 press release*, Takeda Pharmaceuticals U.S.A. Inc. announced that in the case of Jack Cooper et al. v. Takeda Pharmaceuticals America Inc., et al. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court Los Angeles), the jury had awarded $6.5 million in damages to the Plaintiff. In response, Takeda said it filed motions seeking to convince the judge to rule in favor of the company as a matter of law; the company is also considering other options, such as possibly filing an appeal if the judge denies the motions. The trial, which began on February 19, was held in Los Angeles before Judge Kenneth R. Freeman.
“Takeda simply will not accept responsibility for its failure to inform consumers about the link between its drug Actos and bladder cancer, which it was aware of since 2004,” said Matthew J. McCauley, Senior Litigation Counsel at Parker Waichman LLP. "In parts of Europe, this drug was taken off the market in 2011; not only did Takeda keep it on the market here in the U.S., but it couldn’t even revise its warning label to reflect the possible dangers of taking this medication.”
According to an April 16, 2013, Bloomberg report**, a lawyer for the Plaintiff told the jury that Takeda, based on its own internal Actos research, had discovered links between the drug and bladder cancer back in 2004, but that the company didn’t report this to regulators in the U.S. until seven years later. He added that the reason for this was that the company wanted to keep secure its $1.6 billion in annual Actos sales.
According to a March 6, 2013, Bloomberg report***, health regulators from Germany and France ordered the drug to be taken off the market in 2011, after an analysis of a company-sponsored study of the drug revealed that some Actos users faced an increased risk of developing bladder cancer or heart problems.
The U.S. Food and Drug Administration (FDA)**** has warned that taking Actos for one year may significantly increase the risk of bladder cancer. The agency updated the medication’s safety label in 2011 to address these risks. The findings were based on an ongoing 10-year study by Kaiser Permanente.
Last May, the British Medical Journal***** published a study showing that patients who took Actos for two years were twice as likely to develop bladder cancer. In July, a study published in the Canadian Medical Association Journal****** found that Actos users were 22 percent more likely to develop bladder cancer.
Parker Waichman LLP continues to offer free legal consultations to victims of Actos injuries, including bladder cancer, heart problems, and eye injuries. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney